DOCSLIB.ORG

Severe Infectious Diseases of Childhood As Monogenic Inborn Errors of Immunity

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Severe Infectious Diseases of Childhood As Monogenic Inborn Errors of Immunity Severe infectious diseases of childhood as monogenic inborn errors of immunity Jean-Laurent Casanovaa,b,c,d,e,1 aSt. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY 10065; bHoward Hughes Medical Institute, New York, NY 10065; cLaboratory of Human Genetics of Infectious Diseases, Necker Branch, Inserm U1163, Necker Hospital for Sick Children, 75015 Paris, France; dImagine Institute, Paris Descartes University, 75015 Paris, France; and ePediatric Hematology and Immunology Unit, Assistance Publique–Hôpitaux de Paris, Necker Hospital for Sick Children, 75015 Paris, France Contributed by Jean-Laurent Casanova, November 3, 2015 (sent for review September 15, 2015; reviewed by Max D. Cooper and Richard A. Gatti) This paper reviews the developments that have occurred in the normally in other cells. P. vivax infections are rarely lethal today, field of human genetics of infectious diseases from the second half but the selective pressure exerted by this parasite may have fa- of the 20th century onward. In particular, it stresses and explains vored the spread of this allele, which is more common in infested the importance of the recently described monogenic inborn errors areas and is fixed in some African populations. These findings do of immunity underlying resistance or susceptibility to specific infec- not explain the pathogenesis of P. vivax malaria, but they do tions. The monogenic component of the genetic theory provides a explain why some individuals are not infected despite repeated plausible explanation for the occurrence of severe infectious diseases exposure to the parasite. They also show that a pathogen can during primary infection. Over the last 20 y, increasing numbers of favor the spread of a human allele conferring Mendelian pro- life-threatening infectious diseases striking otherwise healthy chil- tection against the pathogen concerned. dren, adolescents, and even young adults have been attributed to single-gene inborn errors of immunity. These studies were inspired Other Forms of Mendelian Resistance to Infection by seminal but neglected findings in plant and animal infections. Another set of similar studies in 1996 explained why the HIV did Infectious diseases typically manifest as sporadic traits because not infect rare individuals in vivo, despite repeated exposure + human genotypes often display incomplete penetrance (most genet- through sexual contact. The CD4 T cells of these individuals ically predisposed individuals remain healthy) and variable expressiv- were shown to be resistant to infection in vitro. An autosomal ity (different infections can be allelic at the same locus). Infectious recessive chemokine (C-C motif) receptor 5 (CCR5) deficiency diseases of childhood, once thought to be archetypal environmental was rapidly identified in these subjects (5–7). The most com- diseases, actually may be among the most genetically determined mon mutation underlying this phenotype probably originated in conditions of mankind. This nascent and testable notion has in- Scandinavia, and the evolutionary forces driving its spread to- teresting medical and biological implications. ward Southern Europe have remained elusive. The third and last case we will consider here is autosomal recessive fucosyl- human genetics | immunology | infectious diseases | pediatrics | transferase 2 (FUT2) deficiency, which was discovered in 2003. primary immunodeficiency Individuals with this deficiency are naturally resistant to diarrhea caused by noroviruses (8, 9). This condition is typically benign in his paper reviews the monogenic inborn errors of immunity the developed world today but would have been potentially life- Tthat have been shown to underlie resistance or vulnerability threatening in ancient times, as it still is in developing countries. to human infectious diseases. These studies, first conducted in With these three examples, we have true genetic determinism the 1970s, gained momentum from the mid-1990s onward. The that is autosomal recessive with complete or almost complete analysis of Mendelian traits was followed by that of non- penetrance. The monogenic lesions prevent infection through a Mendelian monogenic traits, characterized by incomplete clini- cal penetrance and variable expressivity. causal mechanism (i.e., lack of cell infection by a specific microbe). Significance Mendelian Resistance to Malaria An example of infection shaping the human genome was pro- The key problem concerning pediatric infectious diseases, and vided by the discovery of Mendelian resistance to Plasmodium vivax more generally clinical diseases during primary infection, is (1, 2). It is important to stress here that these studies their pathogenesis. A plausible and testable human genetic concerned infection per se and not its manifestations (Table 1). theory of primary infectious diseases has recently emerged, As discussed in the companion paper (3), only a minority of building on elegant studies in plants and animals. Three ex- infected individuals develop clinical disease, and an even smaller amples of monogenic resistance to common infections have minority develop life-threatening disease in the course of pri- been discovered. Moreover, a growing range of monogenic mary infection. Moreover, not all exposed individuals become single-gene inborn errors of immunity, rarely Mendelian (with infected. In at least three cases, this phenomenon has been complete clinical penetrance) but more commonly non- shown to be a Mendelian phenotype because of a well-defined Mendelian (with incomplete penetrance), have been found to monogenic genotype for a microbial receptor or coreceptor. underlie severe infectious diseases striking otherwise healthy Louis Miller carried out pioneering studies in this area. In 1976, children during primary infection. These findings provide a he discovered that an autosomal recessive deficiency of the Duffy synthetic framework for inherited and infectious diseases and, antigen and receptor for chemokines (DARC) in erythrocytes more generally, for inborn and environmental conditions. prevented the infection of these cells with Plasmodium vivax in vitro and the infection of individuals in vivo (1). An elegant set of Author contributions: J.-L.C. designed research, performed research, analyzed data, and follow-up studies demonstrated that this resistance could be at- wrote the paper. tributed to a single nucleotide mutation in the DARC promoter, Reviewers: M.D.C., Emory University; and R.A.G., University of California, Los Angeles. preventing the binding of the transcription factor GATA-binding The authors declare no conflict of interest. protein 1 (GATA1), which is required for DARC expression in Freely available online through the PNAS open access option. the erythrocyte lineage (4). Affected individuals express DARC 1Email: [email protected]. E7128–E7137 | PNAS | Published online November 30, 2015 www.pnas.org/cgi/doi/10.1073/pnas.1521651112 Downloaded by guest on September 25, 2021 Table 1. Mendelian resistance to human infection errors of IFN-γ immunity involving nine genes (19–23). Some PNAS PLUS γ Infection Gene Inheritance Year MSMD-causing genes control the production of IFN- ; others govern its action. These nine MSMD-causing genes display high P. vivax DARC Autosomal recessive 1975 levels of allelic heterogeneity. However, these deficiencies dis- HIV CCR5 Autosomal recessive 1996 play physiological homogeneity, because all defects impair IFN-γ Norovirus FUT2 Autosomal recessive 2003 immunity. Moreover, human IFN-γ immunity, as a quantitative trait, controls host defense against mycobacteria. The clinical The three phenotypes are autosomal recessive. Biallelic mutations underlie γ complete deficiency of any of these three microbial receptors or coreceptors. features of MSMD depend strongly on the levels of IFN- im- These deficiencies can be common, especially in areas where the correspond- munity, being most severe in patients with complete IFN-γ de- ing infection can select the resistance genotype. Clinical penetrance (resistance ficiency (24). The clinical implications of this work are obvious. to infection per se) is complete or almost complete. The infections and re- These studies identified the genetic defects underlying these sistance genes are described in the text, as are the references. Mendelian infections, providing molecular genetic proof that mycobacterial disease could be Mendelian. The patients are treated with IFN-γ and antibiotics or by hematopoietic stem cell These findings concern very large numbers of individuals and neatly transplantation when the receptor is completely nonfunctional. illustrate the potential impact of Mendelian genetics at the pop- The immunological implications are not negligible: These studies ulation level. These findings have important biological implications, confirmed Carl Nathan’s suggestion that IFN-γ is much more a because these three sets of studies demonstrate the essential nature macrophage-activating factor than an antiviral agent (25). They of a single specific gene for each infection. The clinical implications + also showed that the Th1 arm of CD4 T cells (IL-12 being the are equally important, because blocking these molecules in other γ individuals is a rational approach to prevention or therapy. It is Th1-inducing signature cytokine and IFN- the Th1 effector sig- surprising that this field has not blossomed. For almost all common nature cytokine), which in inbred mice
Load more

Recommended publications
  • Comprehensive Genetic Testing for Primary Immunodeficiency
     Woon and Ameratunga Allergy Asthma Clin Immunol (2016) 12:65 Allergy, Asthma & Clinical Immunology DOI 10.1186/s13223-016-0169-2 RESEARCH Open Access Comprehensive genetic testing for primary immunodeficiency disorders in a tertiary hospital: 10‑year experience in Auckland, New Zealand See‑Tarn Woon and Rohan Ameratunga* Abstract Background and purpose: New Zealand is a developed geographically isolated country in the South Pacific with a population of 4.4 million. Genetic diagnosis is the standard of care for most patients with primary immunodeficiency disorders (PIDs). Methods: Since 2005, we have offered a comprehensive genetic testing service for PIDs and other immune-related disorders with a published sequence. Here we present results for this program, over the first decade, between 2005 and 2014. Results: We undertook testing in 228 index cases and 32 carriers during this time. The three most common test requests were for X-linked lymphoproliferative (XLP), tumour necrosis factor receptor associated periodic syndrome (TRAPS) and haemophagocytic lymphohistiocytosis (HLH). Of the 32 suspected XLP cases, positive diagnoses were established in only 2 patients. In contrast, genetic defects in 8 of 11 patients with suspected X-linked agammaglobu‑ linemia (XLA) were confirmed. Most XLA patients were initially identified from absence of B cells. Overall, positive diagnoses were made in about 23% of all tests requested. The diagnostic rate was lowest for several conditions with locus heterogeneity. Conclusions: Thorough clinical characterisation of patients can assist in prioritising which genes should be tested. The clinician-driven customised comprehensive genetic service has worked effectively for New Zealand. Next genera‑ tion sequencing will play an increasing role in disorders with locus heterogeneity.
    [Show full text]
  • Are Complement Deficiencies Really Rare?
    G Model MIMM-4432; No. of Pages 8 ARTICLE IN PRESS Molecular Immunology xxx (2014) xxx–xxx Contents lists available at ScienceDirect Molecular Immunology j ournal homepage: www.elsevier.com/locate/molimm Review Are complement deficiencies really rare? Overview on prevalence, ଝ clinical importance and modern diagnostic approach a,∗ b Anete Sevciovic Grumach , Michael Kirschfink a Faculty of Medicine ABC, Santo Andre, SP, Brazil b Institute of Immunology, University of Heidelberg, Heidelberg, Germany a r a t b i c s t l e i n f o r a c t Article history: Complement deficiencies comprise between 1 and 10% of all primary immunodeficiencies (PIDs) accord- Received 29 May 2014 ing to national and supranational registries. They are still considered rare and even of less clinical Received in revised form 18 June 2014 importance. This not only reflects (as in all PIDs) a great lack of awareness among clinicians and gen- Accepted 23 June 2014 eral practitioners but is also due to the fact that only few centers worldwide provide a comprehensive Available online xxx laboratory complement analysis. To enable early identification, our aim is to present warning signs for complement deficiencies and recommendations for diagnostic approach. The genetic deficiency of any Keywords: early component of the classical pathway (C1q, C1r/s, C2, C4) is often associated with autoimmune dis- Complement deficiencies eases whereas individuals, deficient of properdin or of the terminal pathway components (C5 to C9), are Warning signs Prevalence highly susceptible to meningococcal disease. Deficiency of C1 Inhibitor (hereditary angioedema, HAE) Meningitis results in episodic angioedema, which in a considerable number of patients with identical symptoms Infections also occurs in factor XII mutations.
    [Show full text]
  • Practice Parameter for the Diagnosis and Management of Primary Immunodeficiency
    Practice parameter Practice parameter for the diagnosis and management of primary immunodeficiency Francisco A. Bonilla, MD, PhD, David A. Khan, MD, Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD, David I. Bernstein, MD, Joann Blessing-Moore, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Chief Editor: Francisco A. Bonilla, MD, PhD Co-Editor: David A. Khan, MD Members of the Joint Task Force on Practice Parameters: David I. Bernstein, MD, Joann Blessing-Moore, MD, David Khan, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Primary Immunodeficiency Workgroup: Chairman: Francisco A. Bonilla, MD, PhD Members: Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD GlaxoSmithKline, Merck, and Aerocrine; has received payment for lectures from Genentech/ These parameters were developed by the Joint Task Force on Practice Parameters, representing Novartis, GlaxoSmithKline, and Merck; and has received research support from Genentech/ the American Academy of Allergy, Asthma & Immunology; the American College of Novartis and Merck.
    [Show full text]
  • NIH Public Access Author Manuscript J Allergy Clin Immunol
    NIH Public Access Author Manuscript J Allergy Clin Immunol. Author manuscript; available in PMC 2008 December 12. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: J Allergy Clin Immunol. 2007 October ; 120(4): 776±794. doi:10.1016/j.jaci.2007.08.053. The International Union of Immunological Societies (IUIS) Primary Immunodeficiency Diseases (PID) Classification Committee Raif. S. Geha, M.D., Luigi. D. Notarangelo, M.D. [Co-chairs], Jean-Laurent Casanova, M.D., Helen Chapel, M.D., Mary Ellen Conley, M.D., Alain Fischer, M.D., Lennart Hammarström, M.D., Shigeaki Nonoyama, M.D., Hans D. Ochs, M.D., Jennifer Puck, M.D., Chaim Roifman, M.D., Reinhard Seger, M.D., and Josiah Wedgwood, M.D. Abstract Primary immune deficiency diseases (PID) comprise a genetically heterogeneous group of disorders that affect distinct components of the innate and adaptive immune system, such as neutrophils, macrophages, dendritic cells, complement proteins, NK cells, as well as T and B lymphocytes. The study of these diseases has provided essential insights into the functioning of the immune system. Over 120 distinct genes have been identified, whose abnormalities account for more than 150 different forms of PID. The complexity of the genetic, immunological, and clinical features of PID has prompted the need for their classification, with the ultimate goal of facilitating diagnosis and treatment. To serve this goal, an international Committee of experts has met every two years since 1970. In its last meeting in Jackson Hole, Wyoming, United States, following three days of intense scientific presentations and discussions, the Committee has updated the classification of PID as reported in this article.
    [Show full text]
  • European Society for Immunodeficiencies (ESID)
    Journal of Clinical Immunology https://doi.org/10.1007/s10875-020-00754-1 ORIGINAL ARTICLE European Society for Immunodeficiencies (ESID) and European Reference Network on Rare Primary Immunodeficiency, Autoinflammatory and Autoimmune Diseases (ERN RITA) Complement Guideline: Deficiencies, Diagnosis, and Management Nicholas Brodszki1 & Ashley Frazer-Abel2 & Anete S. Grumach3 & Michael Kirschfink4 & Jiri Litzman5 & Elena Perez6 & Mikko R. J. Seppänen7 & Kathleen E. Sullivan8 & Stephen Jolles9 Received: 5 June 2019 /Accepted: 20 January 2020 # The Author(s) 2020 Abstract This guideline aims to describe the complement system and the functions of the constituent pathways, with particular focus on primary immunodeficiencies (PIDs) and their diagnosis and management. The complement system is a crucial part of the innate immune system, with multiple membrane-bound and soluble components. There are three distinct enzymatic cascade pathways within the complement system, the classical, alternative and lectin pathways, which converge with the cleavage of central C3. Complement deficiencies account for ~5% of PIDs. The clinical consequences of inherited defects in the complement system are protean and include increased susceptibility to infection, autoimmune diseases (e.g., systemic lupus erythematosus), age-related macular degeneration, renal disorders (e.g., atypical hemolytic uremic syndrome) and angioedema. Modern complement analysis allows an in-depth insight into the functional and molecular basis of nearly all complement deficiencies. However, therapeutic options remain relatively limited for the majority of complement deficiencies with the exception of hereditary angioedema and inhibition of an overactivated complement system in regulation defects. Current management strategies for complement disor- ders associated with infection include education, family testing, vaccinations, antibiotics and emergency planning. Keywords Complement .
    [Show full text]
  • Patient & Family Handbook
    Immune Deficiency Foundation Patient & Family Handbook For Primary Immunodeficiency Diseases This book contains general medical information which cannot be applied safely to any individual case. Medical knowledge and practice can change rapidly. Therefore, this book should not be used as a substitute for professional medical advice. SIXTH EDITION COPYRIGHT 1987, 1993, 2001, 2007, 2013, 2019 IMMUNE DEFICIENCY FOUNDATION Copyright 2019 by Immune Deficiency Foundation, USA. Readers may redistribute this article to other individuals for non-commercial use, provided that the text, html codes, and this notice remain intact and unaltered in any way. The Immune Deficiency Foundation Patient & Family Handbook may not be resold, reprinted or redistributed for compensation of any kind without prior written permission from the Immune Deficiency Foundation. If you have any questions about permission, please contact: Immune Deficiency Foundation, 110 West Road, Suite 300, Towson, MD 21204, USA; or by telephone at 800-296-4433. Immune Deficiency Foundation Patient & Family Handbook For Primary Immunodeficiency Diseases 6th Edition The development of this publication was supported by Shire, now Takeda. 110 West Road, Suite 300 Towson, MD 21204 800.296.4433 www.primaryimmune.org [email protected] Editors Mark Ballow, MD Jennifer Heimall, MD Elena Perez, MD, PhD M. Elizabeth Younger, Executive Editor Children’s Hospital of Philadelphia Allergy Associates of the CRNP, PhD University of South Florida Palm Beaches Johns Hopkins University Jennifer Leiding,
    [Show full text]
  • Immunodeficiency Disorders Are a Diverse Group of Illnesses Resulting from One Or More Abnormalities of the Immune System
    World Allergy Organization | Allergic Diseases Resource Center Page 1 of 6 Diagnostic Approach to the Adult with Suspected Immune Deficiency Posted: December 2008 Sasawan Chinratanapisit, M.D. Research Fellow Division of Allergy, Immunology, and Rheumatology University of South Florida, Dept. of Pediatrics Saint Petersburg, FL, USA Panida Sriaroon, M.D. Clinical Fellow Division of Allergy, Immunology, and Rheumatology University of South Florida, Dept. of Pediatrics Saint Petersburg, FL, USA John W. Sleasman, M.D. Robert A. Good Professor and Chief Division of Allergy, Immunology, and Rheumatology University of South Florida, Dept. of Pediatrics Saint Petersburg, FL, USA Select One 1.0 Disease Definition Primary and secondary immunodeficiency disorders are a diverse group of illnesses resulting from one or more abnormalities of the immune system. The clinical manifestations include increased susceptibility to infection and an increased risk for autoimmune disease and malignancy. Primary immune deficiency (PID) diseases are a group of serious disorders arising from an intrinsic defect in the immune system, generally the result of a genetic disease that can be traced directly to a particular immune pathway. In contrast, secondary immune deficiencies stem from impairment of the immune response through another mechanism, such as an infection, metabolic derangement, malignancy or toxins, with the immune defect being a secondary manifestation. Although the possibility of immunodeficiency should be considered in any individual with recurrent
    [Show full text]
  • Pulmonary Complications of Primary Immunodeficiencies
    PAEDIATRIC RESPIRATORY REVIEWS (2004) 5(Suppl A), S225–S233 Pulmonary complications of primary immunodeficiencies Rebecca H. Buckley° Departments of Pediatrics and Immunology, Duke University Medical Center, Durham, NC 27710, USA Summary In the fifty years since Ogden Bruton discovered agammaglobulinemia, more than 100 additional immunodeficiency syndromes have been described. These disorders may involve one or more components of the immune system, including T, B, and NK lymphocytes; phagocytic cells; and complement proteins. Most are recessive traits, some of which are caused by mutations in genes on the X chromosome, others in genes on autosomal chromosomes. Until the past decade, there was little insight into the fundamental problems underlying a majority of these conditions. Many of the primary immunodeficiency diseases have now been mapped to specific chromosomal locations, and the fundamental biologic errors have been identified in more than 3 dozen. Within the past decade the molecular bases of 7 X-linked immunodeficiency disorders have been reported: X-linked immunodeficiency with Hyper IgM, X-linked lymphoproliferative disease, X-linked agammaglobulinemia, X-linked severe combined immunodeficiency, the Wiskott–Aldrich syndrome, nuclear factor úB essential modulator (NEMO or IKKg), and the immune dysregulation polyendocrinopathy (IPEX) syndrome. The abnormal genes in X-linked chronic granulomatous disease (CGD) and properdin deficiency had been identified several years earlier. In addition, there are now many autosomal recessive immunodeficiencies for which the molecular bases have been discovered. These new advances will be reviewed, with particular emphasis on the pulmonary complications of some of these diseases. In some cases there are unique features of lung abnormalities in specific defects.
    [Show full text]
  • Primary Immunodeficiency Diseases in Latin America: First Report from Eight Countries Participating in the LAGID1
    Journal of Clinical Immunology, Vol. 18, No. 2, 1998 Primary Immunodeficiency Diseases in Latin America: First Report from Eight Countries Participating in the LAGID1 MARTA ZELAZKO,2 MAGDA CARNEIRO-SAMPAIO,3 MONICA CORNEJO DE LUIGI,4 DIANA GARCIA DE OLARTE,5 OSCAR PORRAS MADRIGAL,6 RENATO BERRON PEREZ,7 AGUEDA CABELLO,8 MARYLIN VALENTIN ROSTAN,9 and RICARDO U. SORENSEN10 Accepted: November 6, 1997 INTRODUCTION The Latin American Group for Primary Immunodeficiencies, Knowledge about primary immunodeficiency diseases (PID) formed in 1993, presently includes 12 countries. One goal was and their diagnosis and treatment is still fragmentary in many to study the frequency of primary immunodeficiencies in countries. Physicians and health-care authorities are often various regions of the American continent and to enhance poorly informed about the clinical presentation, diagnosis, knowledge about these diseases among primary-care physi- importance and health impact of these diseases. In response to cians, as well as allergist-immunologists. Important for this this situation, clinical immunologists in several Latin Ameri- purpose was the development of a registry of primary immu- can countries took the initiative in creating registries of PID. nodeficiencies using a uniform questionnaire and computerized database. To date, eight countries have collected information The results of these early efforts in Argentina, Brazil, Chile, on a total of 1428 patients. Predominantly antibody deficiencies and Colombia were presented and discussed at the III Con-
    [Show full text]
  • Investigation for Complement Deficiency Following Meningococcal Disease S Hoare, O El-Shazali, J E Clark, a Fay, a J Cant
    215 ORIGINAL ARTICLE Arch Dis Child: first published as 10.1136/adc.86.3.215 on 1 March 2002. Downloaded from Investigation for complement deficiency following meningococcal disease S Hoare, O El-Shazali, J E Clark, A Fay, A J Cant ............................................................................................................................. Arch Dis Child 2002;86:215–217 See end of article for authors’ affiliations Background and aims: The incidence of complement abnormalities in the UK is not known. It is sug- ....................... gested in at least three major paediatric textbooks to test for abnormalities of the complement system Correspondence to: following meningococcal disease (MCD). Dr S Hoare, Paediatric Methods: Over a four year period, surviving children with a diagnosis of MCD had complement activ- Infectious Diseases Unit, ity assessed. A total of 297 children, aged 2 months to 16 years were screened. Newcastle General Results: All children except one had disease caused by B or C serogroups. One child, with group B Hospital, Westgate Rd, meningococcal septicaemia (complicated by disseminated intravascular coagulation and who required Newcastle upon Tyne NE4 6BE, UK; ventilation and inotropic support) was complement deficient. C2 deficiency was subsequently simon.hoare@ diagnosed. She had other major pointers towards an immunological abnormality prior to her MCD. dial.pipex.com Conclusion: It is unnecessary to screen all children routinely following MCD if caused by group B or Accepted C infection. However, it is important to assess the previous health of the child and to investigate appro- 22 November 2001 priately if there have been previous suspicious infections, abnormal course of infective illnesses, or if ....................... this is a repeated episode of neisserial infection.
    [Show full text]
  • Download CGT Exome V2.0
    CGT Exome version 2.
    [Show full text]
  • Carrier Screening Panel
    Advancing Non-Invasive Healthcare Cell3TM Target: Carrier Screening Panel Detects 448 childhood recessive disorders DISORDER GENE DISEASE TYPE 2-Methylbutryl-CoA dehydrogenase deficiency ACADSB Metabolic 3-Hydroxy-3-methylglutaryl- CoA lyase deficiency HMGCL Metabolic 3-Hydroxyacyl- CoA dehydrogenase deficiency HADH Metabolic 3-Methylcrotonyl- CoA carboxylase 2 deficiency MCCC2 Metabolic 3-Methylglutaconic aciduria, i AUH Metabolic 3-Methylglutaconic aciduria, iii OPA3 Metabolic 3-Methylglutaconic aciduria, v DNAJC19 Metabolic α -Thalassemia/mental retardation syndrome, nondeletion, XLR ATRX ATRX Hematologic ABCD syndrome EDNRB Cutaneous Abetalipoproteinemia; ABL MTTP Metabolic Achalasia-Addisonianism-Alacrima syndrome; AAA AAAS Endocrine Achondrogenesis, Ib; ACG1b SLC26A2 Skeletal Achromatopsia 3; ACHM3 CNGB3 Ocular Acrocallosal syndrome; ACLS GLI3 Developmental Acyl-CoA dehydrogenase family, member 9, deficiency of ACAD9 Metabolic Acyl-CoA dehydrogenase, long-chain, deficiency of ACADL Metabolic Acyl-CoA dehydrogenase, medium-chain, deficiency of ACADM Metabolic Acyl-CoA dehydrogenase, short-chain, deficiency of ACADS Metabolic Acyl-CoA dehydrogenase, very long-chain, deficiency of ACADVL Metabolic Adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency CYP21A2 Endocrine Adrenoleukodystrophy; ALD ABCD1 Neurological Afibrinogenemia, congenital FGA Hematologic Afibrinogenemia, congenital FGB Hematologic Afibrinogenemia, congenital FGG Hematologic Agammaglobulinemia, XLR, XLA BTK Immunodeficiency Agenesis of the corpus callosum
    [Show full text]